David P Steensma, M.D.

Dana-Farber Cancer InstituteBoston, Massachusetts - 02115 |
- CLINICAL TRIALS 1
- CONDITIONS2
- INTERVENTIONS2
- SINCE2009

Dose-Ranging Study of Telintra Tablets + Revlimid in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
November 2009 - May 2012
Myelodysplastic Syndromes
Preleukemia
Lenalidomide (Revlimid®)
Ezatiostat Hydrochloride



